Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

Inclusion Criteria

• •Individuals who meet all of the following criteria are eligible for enrollment as study participants:
• •1. Chinese patients,aged 6 years and older，female or male
• •2. Diagnosed as allergic asthma according to the guideline for Chinese guidelines for the diagnosis and treatment of allergic asthma（2019，the first edition）
• •3. Meet the diagnostic criteria for moderate and severe asthma, in line with the diagnostic standards of the GINA (Global Initiative for Asthma)，it refers to those who can achieve complete control under the GINA Step 3 treatment; for severe asthma, it refers to those who need Step 4 or Step 5 treatment to achieve complete control, or those who still cannot achieve control even after undergoing Step 4 or Step 5 treatment.
• •4. The patients included in the study were positive for specific immunoglobulin E (sIgE), or had a positive skin prick test (SPT) with D.pteronyssinus and D. farinae allergens.
• •5. Patients who will initiate AIT or omalizumab combined with AIT according to real life clinical standards of practice.